Abstract: A product comprising a natural acellular xenogenic vascular tissue matrix having at least an 80% reduction in DNA content as compared to an untreated control vascular tissue matrix and being antigenically inert by being substantially free of epitopes capable of reacting with pre-formed human antibodies and also without having the ability to substantially activate complement. The invention also includes methods of preparing such products and uses of the products especially in bypass surgery.
Type:
Grant
Filed:
September 26, 2011
Date of Patent:
December 6, 2016
Assignee:
Tissue Regenix Limited
Inventors:
Eileen Ingham, John Fisher, Stacy-Paul Wilshaw
Abstract: The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularisation is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro.
Type:
Grant
Filed:
July 29, 2014
Date of Patent:
November 10, 2015
Assignee:
Tissue Regenix Limited
Inventors:
Fiona Bolland, Jennifer Southgate, Sotirios Korossis, Eileen Ingham
Abstract: The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularization is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro.
Type:
Grant
Filed:
July 29, 2014
Date of Patent:
November 10, 2015
Assignee:
Tissue Regenix Limited
Inventors:
Fiona Bolland, Jennifer Southgate, Sotirios Korossis, Eileen Ingham
Abstract: The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularization is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro.
Type:
Grant
Filed:
March 28, 2007
Date of Patent:
September 9, 2014
Assignee:
Tissue Regenix Limited
Inventors:
Sotirios Korossis, Eileen Ingham, Fiona Bolland, Jennifer Southgate
© 2024 Justia
